FDA expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia. The drug received a breakthrough therapy designation for this use.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
